Pulmonary hypertension (PH) is widely recognized as a disease driven by both vasoconstriction and vascular remodeling. Vasoconstriction is thought to play a predominant role in the early stages of PH, whereas the contribution of vascular remodeling increases as the disease progresses. However, clinical or histological evidence of this pathological progression has not been reported.
Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology. In recent years, increasing evidence has demonstrated that endothelial dysfunction contributes to the progression of various lung diseases, such as ADRS, PF, PH, and lung developmental disorders.
Early identification of pulmonary vascular disease remains a major unmet need in systemic sclerosis. In this context, the study by Kagami and colleagues provides important insights into the role of exercise stress echocardiography in detecting early hemodynamic abnormalities.
This webinar explores Group 3 pulmonary hypertension (PH) associated with COPD and ILD, including updated definitions, diagnosis, and treatment approaches.
Ten patients with post-COVID ILD-PH are described. This complication occurred only in patients after prolonged intensive care (ICU) admission for invasive mechanical ventilation.
Pregnancy in pulmonary arterial hypertension (PAH) is associated with substantial risks. Endothelin receptor antagonists (ERAs), including macitentan and bosentan, are contraindicated in pregnancy due to teratogenic effects observed in animal studies.
Invasive exercise hemodynamics are used to diagnose heart failure with preserved ejection fraction (HFpEF), based on pulmonary artery wedge pressure (PAWP) or left atrial (LA) pressure elevations.
Pretreatment with targeted pulmonary arterial hypertension (PAH) therapy in adults with unrepaired atrial septal defects (ASDs) has been increasingly reported as a means to improve pulmonary hemodynamics and expand candidacy for defect closure.
A dry powder inhaler (DPI) formulation of treprostinil was FDA-approved in March 2022 for patients with pulmonary arterial hypertension or pulmonary hypertension associated with ILD (PH-ILD).
